Type VI Protein Secretion in an Emerging Multidrug-Resistant Pathogen

新兴多重耐药病原体中的 VI 型蛋白分泌

基本信息

  • 批准号:
    8681327
  • 负责人:
  • 金额:
    $ 5.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-03 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hospital-acquired infections due to multidrug-resistant bacteria are a major cause of increased morbidity and mortality in patients with weakened immunity. A leading agent of such infections is the bacterium Acinetobacter baumannii. This microbe causes invasive infections, including pneumonia and sepsis, that in recent years have become increasingly severe and antibiotic-resistant, raising the specter that they may one day be untreatable. New ways to prevent and treat infections with A. baumannii are urgently needed, but alarmingly little is known about how these bacteria cause disease. Recent evidence indicates that these bacteria induce adherence-dependent cytotoxicity toward cultured epithelial cells; however, the mechanisms used by A. baumannii to intoxicate cells upon adhesion are unclear. The goal of the proposed studies is to understand how these microbes interact with human cells and how such interactions undermine normal cellular processes, promoting infection. Towards this goal, this proposal aims to characterize in detail a contact-dependent protein delivery system, known as a Type VI Secretion System (T6SS) that is present in clinical strains of A. baumannii responsible for recent epidemics. These systems play a role in host infections by a range of microbes, but the system is undefined in A. baumannii. The proposed work will determine which cells are targeted by the A. baumannii T6SS, identify the effector proteins it sends into these cells, and examine the functional roles of the system and its effectors in host interactions and pathogenesis. These aims will be accomplished by analyzing the transfer of reporter fusions into target cells, conducting directed genome-wide screens for effectors, and examining the effects of T6SS- and effector-null mutants on bacterial toxicity and the host innate immune response during interactions with host cells in culture and in a murine model of pneumonia. These studies will break new ground on the mechanisms used by A. baumannii to promote infection and will address key gaps in our understanding of T6SS pathobiology. Ultimately, this information will uncover targets for novel anti-infective treatments and vaccines against highly drug- resistant bacteria. The training experience will broaden my expertise in molecular biology, teach me new techniques in mammalian cell culture and animal models, and advance my understanding of the pathogenesis of infectious diseases.
描述(由申请方提供):多重耐药菌引起的医院获得性感染是免疫力低下患者发病率和死亡率增加的主要原因。这种感染的主要病原体是细菌鲍氏不动杆菌。这种微生物会导致包括肺炎和败血症在内的侵袭性感染,近年来这些感染变得越来越严重,越来越耐药,这让人们担心它们可能有一天无法治愈。预防和治疗A.鲍曼不动杆菌是迫切需要的,但令人震惊的是,人们对这些细菌如何引起疾病知之甚少。最近的证据表明,这些细菌诱导粘附依赖性细胞毒性对培养的上皮细胞;鲍曼不动杆菌在粘附时致毒细胞的作用尚不清楚。拟议研究的目标是了解这些微生物如何与人类细胞相互作用,以及这种相互作用如何破坏正常的细胞过程,促进感染。为了实现这一目标,本提案旨在详细描述接触依赖性蛋白质递送系统,称为VI型分泌系统(T6 SS),其存在于A.鲍曼不动杆菌导致了最近的流行病。这些系统在一系列微生物的宿主感染中发挥作用,但该系统在A.鲍曼不动杆菌。拟议的工作将确定A.鲍曼不动杆菌T6 SS,确定它发送到这些细胞的效应蛋白,并检查系统及其效应器在宿主相互作用和发病机制中的功能作用。这些目标将通过分析报告融合转移到靶细胞,进行定向全基因组筛选效应子,并检查T6 SS和效应子无效突变体对细菌毒性和宿主先天免疫反应的影响,在培养和小鼠肺炎模型中与宿主细胞相互作用。这些研究将为A.鲍曼不动杆菌促进感染,并将解决我们对T6 SS病理生物学理解的关键差距。最终,这些信息将揭示新型抗感染治疗的目标 以及针对高抗药性细菌的疫苗。培训经验将拓宽我在分子生物学方面的专业知识,教我哺乳动物细胞培养和动物模型的新技术,并提高我对传染病发病机制的理解。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Landscape of Phenotypic and Transcriptional Responses to Ciprofloxacin in Acinetobacter baumannii: Acquired Resistance Alleles Modulate Drug-Induced SOS Response and Prophage Replication
  • DOI:
    10.1128/mbio.01127-19
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Geisinger, Edward;Vargas-Cuebas, German;Isberg, Ralph R.
  • 通讯作者:
    Isberg, Ralph R.
Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii.
  • DOI:
    10.1371/journal.ppat.1004691
  • 发表时间:
    2015-02
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Geisinger E;Isberg RR
  • 通讯作者:
    Isberg RR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward Geisinger其他文献

Edward Geisinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward Geisinger', 18)}}的其他基金

Global Circuitry that Controls Acinetobacter Resistance and Virulence
控制不动杆菌耐药性和毒力的全球电路
  • 批准号:
    10651743
  • 财政年份:
    2021
  • 资助金额:
    $ 5.87万
  • 项目类别:
Global Circuitry that Controls Acinetobacter Resistance and Virulence
控制不动杆菌耐药性和毒力的全球电路
  • 批准号:
    10456181
  • 财政年份:
    2021
  • 资助金额:
    $ 5.87万
  • 项目类别:
Global Circuitry that Controls Acinetobacter Resistance and Virulence
控制不动杆菌耐药性和毒力的全球电路
  • 批准号:
    10279655
  • 财政年份:
    2021
  • 资助金额:
    $ 5.87万
  • 项目类别:
Type VI Protein Secretion in an Emerging Multidrug-Resistant Pathogen
新兴多重耐药病原体中的 VI 型蛋白分泌
  • 批准号:
    8450982
  • 财政年份:
    2012
  • 资助金额:
    $ 5.87万
  • 项目类别:
Type VI Protein Secretion in an Emerging Multidrug-Resistant Pathogen
新兴多重耐药病原体中的 VI 型蛋白分泌
  • 批准号:
    8254576
  • 财政年份:
    2012
  • 资助金额:
    $ 5.87万
  • 项目类别:

相似海外基金

Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.87万
  • 项目类别:
    Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
  • 批准号:
    477936
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
    Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
  • 批准号:
    494854
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
    Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
  • 批准号:
    488684
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
    Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
  • 批准号:
    23K14346
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
  • 批准号:
    10674406
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
  • 批准号:
    10677362
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
  • 批准号:
    10625029
  • 财政年份:
    2023
  • 资助金额:
    $ 5.87万
  • 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
  • 批准号:
    10596620
  • 财政年份:
    2022
  • 资助金额:
    $ 5.87万
  • 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
  • 批准号:
    10449699
  • 财政年份:
    2022
  • 资助金额:
    $ 5.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了